EXCLUSIVE: Immix CEO On FDA Designation, Positioning, Price Action On 'Benzinga Live'
Immix Biopharma Inc (NASDAQ: IMMX) stock is soaring Monday after the U.S. Food and Drug Administration granted Rare Pediatric Disease designation for IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening form of pediatric cancer in children.
